Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Ribomic, Inc. ( (JP:4591) ).
Ribomic Inc. reported its non-consolidated financial results for the fiscal year ending March 31, 2025, showing a continued net loss with operating revenues at 2 million yen and a net loss of 1,018 million yen. Despite the financial challenges, the company maintains a strong equity ratio of 95.5% and has scheduled a financial results meeting for institutional investors and analysts, indicating a proactive approach to stakeholder communication.
More about Ribomic, Inc.
Ribomic Inc. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. The company focuses on developing innovative RNA aptamer-based therapeutics, which are a class of molecules used in the treatment of various diseases.
Average Trading Volume: 2,289,114
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen3.79B
For an in-depth examination of 4591 stock, go to TipRanks’ Stock Analysis page.